Silverleafe Capital Partners LLC Invests $939,000 in Tempus AI, Inc. $TEM

Silverleafe Capital Partners LLC bought a new stake in Tempus AI, Inc. (NASDAQ:TEM) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,897 shares of the company’s stock, valued at approximately $939,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cranbrook Wealth Management LLC acquired a new position in Tempus AI in the 3rd quarter worth $25,000. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at about $26,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI in the third quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI in the 3rd quarter valued at $38,000. Finally, Tsfg LLC lifted its holdings in Tempus AI by 1,515.2% during the 3rd quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after purchasing an additional 500 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insider Activity at Tempus AI

In related news, EVP Andrew Polovin sold 10,949 shares of the stock in a transaction on Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president directly owned 126,918 shares of the company’s stock, valued at $7,654,424.58. This represents a 7.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total transaction of $10,899,350.00. Following the completion of the sale, the chief executive officer owned 8,941,533 shares of the company’s stock, valued at $586,206,903.48. The trade was a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 402,591 shares of company stock worth $24,868,936 over the last ninety days. 26.27% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TEM. BTIG Research decreased their price target on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Canaccord Genuity Group cut their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. JPMorgan Chase & Co. decreased their target price on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Finally, Stifel Nicolaus set a $60.00 price objective on shares of Tempus AI in a research note on Wednesday, February 25th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.62.

Tempus AI Stock Down 4.2%

Tempus AI stock opened at $46.76 on Thursday. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. The firm has a 50 day moving average price of $56.13 and a two-hundred day moving average price of $70.16. The firm has a market cap of $8.36 billion, a price-to-earnings ratio of -33.16 and a beta of 5.29.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.